King Pharmaceuticals is aiming to file New Drug Applications for three products, including its pharmacologic stress-imaging agent called CorVue, with the FDA by the end of the year. "Once approved, these new products have the potential to provide significant value for patients, society and our shareholders," King CEO Brian Markison said.

Full Story:

Related Summaries